> Details

Perry, Anamarija M.; Cardesa-Salzmann, Teresa M.; Meyer, Paul N.; Colomo, Luis; Smith, Lynette M.; Fu, Kai; Greiner, Timothy C.; Delabie, Jan; Gascoyne, Randy D.; Rimsza, Lisa; Jaffe, Elaine S.; Ott, German; Rosenwald, Andreas; Braziel, Rita M.; Tubbs, Raymond; Cook, James R.; Staudt, Louis M.; Connors, Joseph M.; Sehn, Laurie H.; Vose, Julie M.; López-Guillermo, Armando; Campo, Elias; Chan, Wing C.; Weisenburger, Dennis D.

A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma
  • Contributor: Perry, Anamarija M.; Cardesa-Salzmann, Teresa M.; Meyer, Paul N.; Colomo, Luis; Smith, Lynette M.; Fu, Kai; Greiner, Timothy C.; Delabie, Jan; Gascoyne, Randy D.; Rimsza, Lisa; Jaffe, Elaine S.; Ott, German; Rosenwald, Andreas; Braziel, Rita M.; Tubbs, Raymond; Cook, James R.; Staudt, Louis M.; Connors, Joseph M.; Sehn, Laurie H.; Vose, Julie M.; López-Guillermo, Armando; Campo, Elias; Chan, Wing C.; Weisenburger, Dennis D.
  • Published: American Society of Hematology, 2012
  • Published in: Blood, 120 (2012) 11, Seite 2290-2296
  • Language: English
  • DOI: 10.1182/blood-2012-05-430389
  • ISSN: 0006-4971; 1528-0020
  • Origination:
  • Footnote:
  • Description: Abstract Biologic factors that predict the survival of patients with a diffuse large B-cell lymphoma, such as cell of origin and stromal signatures, have been discovered by gene expression profiling. We attempted to simulate these gene expression profiling findings and create a new biologic prognostic model based on immunohistochemistry. We studied 199 patients (125 in the training set, 74 in the validation set) with de novo diffuse large B-cell lymphoma treated with rituximab and CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or CHOP-like therapies, and immunohistochemical stains were performed on paraffin-embedded tissue microarrays. In the model, 1 point was awarded for each adverse prognostic factor: nongerminal center B cell–like subtype, SPARC (secreted protein, acidic, and rich in cysteine) < 5%, and microvascular density quartile 4. The model using these 3 biologic markers was highly predictive of overall survival and event-free survival in multivariate analysis after adjusting for the International Prognostic Index in both the training and validation sets. This new model delineates 2 groups of patients, 1 with a low biologic score (0-1) and good survival and the other with a high score (2-3) and poor survival. This new biologic prognostic model could be used with the International Prognostic Index to stratify patients for novel or risk-adapted therapies.
  • Access State: Open Access